



Date: Friday, November 9<sup>th</sup>, 2018

Location: "Keep Memory Alive" Event Center

Cleveland Clinic's Lou Ruvo Center for Brain Health

Sponsor: GB Sciences, Inc. (OTCQB:GBLX)

### "INNOVATION IN MEDICAL CANNABIS THERAPIES"

GB Sciences invites top innovators in cannabis tech, biotech, nanotech, and metabolomics to this collaborative discussion designed to explore the necessary advances across multiple fields required for the development of safe and effective plant-based medicines.

#### PROPOSED AGENDA-NOVEMBER 9th

8:30am to 9:00am REGISTRATION and BREAKFAST BUFFET

9:00am to 9:10am KEYNOTE ADDRESS by *Dr. Zoltan Mari, Director of the PD and Movement Disorders Program and The Ruvo Family Chair, Cleveland Clinic Lou Ruvo Center for Brain Health*

9:15am to 9:30am CANNABIS INDUSTRY CHALLENGE: What can the industry do better or differently to serve the needs of medical patients and to be taken seriously in the medical space? by *Dr. Andrea Small-Howard, CSO & Director of GB Sciences, Inc.*

9:35am to 10:15am PATIENT NEEDS: A Physician-Patient-Caregiver Dialogue

- What aspects are working in state-run "safe access" programs for patients & caregivers?
- What is missing? How could medical cannabis products be improved?
- How could the system be modified to ensure patient's medical needs are met?

*Led by Dr. Zoltan Mari (Cleveland Clinic), Parkinson's patient spokesperson and their caregiver, Jamillah Ali-Rahman (CEO, Friends of Parkinson's), and Meredith Patterson (RN, Brainstorm Mind Fitness).*

10:20am to 11:00am CREATING AH-HA MOMENTS IN THE LAB: How do disease processes inform cannabis research goals?

- Metabolomics & Screening Techniques
- Models of Disease-Cellular & Animal
- Special Opportunities & Challenges within Cannabis Research

*Led by Dr. Helen Turner (Chaminade University), Dr. Norbert Kaminski (Michigan State University), Dr. Alexander Stokes (University of Hawai'i), Dr. Maria Halabalaki (Univ. of Athens), Dr. Lisa Truong (Oregon State University), and Dr. Mark Speck (Chaminade University)*

11:00am to 11:15am COFFEE BREAK

11:20am to 12:00pm CULTIVATION: THE PLANT AS A MEDICINE

- For many patients, dried flower is their medicine (sleeping, appetite, anti-anxiety, etc.)
- What combination of techniques and technologies help to ensure safety and consistency from batch to batch?
- What can be done to improve upon the current industry standards?

*Led by Dr. Philip Elzer (Executive Assoc. Dean, LSU Ag Center), Dr. Ulrich Reimann-Philipp (Lead Botanist, GB Sciences Louisiana), Brent Perkins (President & COO, Scynce LED), Dani Fontaine (Colorado Hemp Project), and Steve Joyner (Quantum Shop)*

12:05pm to 12:45pm EXTRACTION: WHOLE PLANT EXTRACTS VERSUS ISOLATED COMPOUNDS. What's better for the Patient? An informal debate...

*Led by Tom Arcuragi (CMO, GB Sciences), Dr. Eleftherios Petrakis (University of Athens), Dr. Shane Johnson (BayMedica, LLC), and Dr. Dominick Monaco (GM, GB Sciences)*



### **“INNOVATION IN MEDICAL CANNABIS THERAPIES”**

GB Sciences invites top innovators in cannabis tech, biotech, nanotech, and metabolomics to this collaborative discussion designed to explore the necessary advances across multiple fields required for the development of safe and effective plant-based medicines.

#### **PROPOSED AGENDA-NOVEMBER 9th**

- 12:45pm to 1:45pm**      **LUNCH, NETWORKING, SCIENTIFIC POSTER SESSION:** Featuring posters from a variety of scientific disciplines related to cannabis. Includes tissue culture, growing techniques, metabolomics & specific research models
- 1:50pm to 2:30pm**      **DOSING & DELIVERY SYSTEMS:** Matching Pharmacodynamic Challenges to Disease Processes; Bioavailability to Meet Patient Needs (gel caps, tinctures, patches, creams, inhalers, tablets, and nanomedicine)  
*Led by Dr. Andrea Small-Howard (GB Sciences), Dr. Mercedes Fernández Arévalo (University of Seville, Spain), Dr. Lucia Martin Banderas (University of Seville), Scott Schaneville (Striptiva, LLC), and Dr. David Fulper (Catalent Pharma Solutions)*
- 2:35pm to 3:15pm**      **CLINICAL TRIALS: Challenges & Opportunities**
- Challenges/Opportunities through the US FDA versus International Clinical Trials
  - US FDA Process = FDA, DEA, and NIDA; Sole Source of Medical Cannabis from Ole Miss
  - US Trials done under State Cannabis Programs versus Federal FDA-Registration (Pros/Cons)
- Led by Dr. Carlos Rios-Bedoya (McLaren Health), Dr. Ziva Cooper (Columbia University), Dr. Michael Murphy (Founder, World Wide Clinical), and Dr. Amrit Seetharam (CurAccel)*
- 3:15pm to 3:30pm**      **COFFEE BREAK & SNACKS**
- 3:35pm to 4:05pm**      **LEGISLATIVE:** Need for industry involvement in driving positive change  
What areas could be improved, potentially state-by-state, to enhance the effectiveness of Cannabis Research and legitimization of Cannabis as Medicine?  
*Led by Elizabeth Ashford (Founder, Ceres Strategies), Richard S. "Tick" Segerblom (Nevada State Senator), John Davis (President, GB Sciences Louisiana), and Sandra Tiffany (Owner, GWGA, LLC and former Nevada State Senator)*
- 4:10pm to 4:40pm**      **CHANGING THE PARADIGM:** Moving Cannabis from Alternative to Mainstream Medicine. What are the barriers? What are the opportunities; ie, decreased national dependence on opioids?  
*Led by Dr. Dominick Monaco (GM, GB Sciences), Brenda Gunsallas (Sahara Wellness), James Patterson (Nevada Dispensary Association), and Dr. Andrea Small-Howard (CSO, GB Sciences)*
- 4:45pm to 5:00pm**      **TAKE-AWAYS FROM THE AUDIENCE:** Live Feedback from This Event  
*Moderated by Dr. Michael Farley, Valor Management, S.A.*
- 5:00pm to 5:10pm**      **CLOSING REMARKS** by John Poss, CEO & Chairman of GB Sciences, Inc.